Immunovant Shares Rise on Positive Clinical Trial Results Despite Earnings Miss
Despite reporting a wider-than-expected fourth-quarter loss of $0.73 per share, Immunovant's shares rose in pre-market trading due to positive clinical trial results for its lead drug candidate IMVT-1402. The encouraging data from the rheumatoid arthritis study drove investor optimism.
Tickers: $IMVT
Topics: drug development pharmaceuticals rheumatoid arthritis